Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Parisi Gray Wealth Management

Parisi Gray Wealth Management lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.8% during the 4th quarter, HoldingsChannel reports. The firm owned 8,056 shares of the biopharmaceutical company’s stock after selling 678 shares during the quarter. Parisi Gray Wealth Management’s holdings in Pfizer were worth $232,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. State Street Corp increased its stake in shares of Pfizer by 1.9% in the second quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock valued at $10,534,558,000 after buying an additional 5,374,611 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley lifted its stake in Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after acquiring an additional 348,628 shares in the last quarter. Finally, Norges Bank bought a new stake in Pfizer in the 4th quarter valued at approximately $3,150,472,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.07 during mid-day trading on Thursday, hitting $27.85. 4,432,768 shares of the stock were exchanged, compared to its average volume of 43,242,164. The company has a market cap of $157.70 billion, a PE ratio of 77.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The firm has a fifty day moving average of $27.47 and a 200 day moving average of $29.47. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. The business’s revenue was down 41.3% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. UBS Group lowered their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.